Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
15-Year watch begins for gene therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 40 people who have already received CLBR001, a gene therapy that uses a lentivirus to deliver a chimeric antigen receptor. Researchers will monitor participants for 15 years to detect any delayed side effects or safety issues. The goal is to understand the long…
Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:50 UTC